We hypothesized, inspired by Albaqumi et al. (32), that Kcnn4 genetic inactivation or pharmacological inhibition of KCa3.1 would effectively treat ADPKD, as KCa3.1 inhibitor senicapoc has shown both target engagement and tolerability in human trials. This evidence concerns the gene KCNN4 and autosomal dominant polycystic kidney disease.